

ONE HUNDRED EIGHTEENTH CONGRESS  
**Congress of the United States**  
**House of Representatives**  
COMMITTEE ON ENERGY AND COMMERCE  
2125 RAYBURN HOUSE OFFICE BUILDING  
WASHINGTON, DC 20515-6115  
Majority (202) 225-3641  
Minority (202) 225-2927

February 22, 2024

**Committee on Energy and Commerce**  
***Subcommittee on Health***

**HEARING NOTICE**

The Subcommittee on Health has scheduled a hearing on Thursday, February 29, 2024, at 10:00 a.m. (ET). The hearing will take place in 2123 Rayburn House Office Building. The title of the hearing is “Legislative Proposals to Support Patients with Rare Diseases.” Witnesses will be announced and are by invitation only. In addition, hearings are open to audio, video, and photographic coverage by accredited press representatives only. The hearing will be open to the public. The hearing may also be viewed via live webcast on the Committee’s website: <http://energycommerce.house.gov>.

The hearing will focus on the following legislation:

- **H.R. 1092, Better Empowerment Now to Enhance Framework and Improve Treatments (BENEFIT) Act (Reps. Matsui and Wenstrup)**
- **H.R. 3433, Give Kids a Chance Act (Reps. McCaul and Eshoo)**
- **H.R. 4758, Accelerating Kids Access to Care Act (Reps. Trahan and Miller-Meeks)**
- **H.R. 5539, Optimizing Research Progress Hope And New (ORPHAN) Cures Act (Reps. Joyce and Nickel)**
- **H.R. 5547, Maintaining Investments in New Innovation (MINI) Act (Reps. Nickel and Joyce)**
- **H.R. 5663, ALS Better Care Act (Reps. Schakowsky, Quigley, and Fitzpatrick)**
- **H.R. 6020, Honor Our Living Donors Act (Reps. Obernolte and DelBene)**
- **H.R. 6094, Providing Realistic Opportunity To Equal and Comparable Treatment for (PROTECT) Rare Act (Reps. Matsui and Dunn)**
- **H.R. 6465, Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act (Reps. Hudson and Davis)**
- **H.R. 6664, Innovation in Pediatric Drugs Act (Reps. Eshoo and McCaul)**
- **H.R. 6705, Effective Screening and Testing for Tuberculosis Act (Reps. Moolenaar and Dingell)**

- **H.R. 7188, Shandra Eisenga Human Cell and Tissue Product Safety Act (Reps. Moolenaar and Dingell)**
- **H.R. 7248, FDA Modernization Act 3.0 (Reps. Carter and Barragán)**
- **H.R. 7383, Retaining Access and Restoring Exclusivity (RARE) Act (Reps. Matsui and Bilirakis)**
- **H.R. 7384, Creating Hope Reauthorization Act of 2024 (Reps. McCaul and Eshoo)**
- **H.R. \_\_\_\_, Antimicrobial Resistance Research Assessment Act (Rep. Griffith)**
- **H.R. \_\_\_\_, Patient Access Act (Rep. Guthrie)**
- **H.R. \_\_\_\_, Sickle Cell Disease Comprehensive Care Act (Rep. Burgess)**

If you have any questions concerning this hearing, please contact Emma Schultheis at [Emma.Schultheis@mail.house.gov](mailto:Emma.Schultheis@mail.house.gov).

By Order of Chair Guthrie

*The Committee on Energy and Commerce endeavors to make its facilities accessible to persons with disabilities. If you are in need of special accommodations, or have any questions regarding special accommodations generally, please contact the Committee in advance of the scheduled event (4 business days' notice is requested) at (202) 225-3641 or 2125 Rayburn House Office Building.*